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Abstract
Background: Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system in
young adults. Despite the fact that numerous lines of evidence link both the risk of disease development and the
disease course to the serum level of 25-hydroxyvitamin D it still remains elusive whether multiple sclerosis patients
benefit from boosting the serum level of 25-hydroxyvitamin D, mainly because interventional clinical trials that
directly address the therapeutic effects of vitamin D in multiple sclerosis are sparse. We here present the protocol
of an interventional clinical phase II study to test the hypothesis, that high-dose vitamin D supplementation of
multiple sclerosis patients is safe and superior to low-dose supplementation with respect to beneficial therapeutic
effects.
Methods/Design: The EVIDIMS trial is a German multi-center, stratified, randomized, controlled and double-blind
clinical phase II pilot study. Eighty patients with the diagnosis of definite multiple sclerosis or clinically isolated
syndrome who are on a stable immunomodulatory treatment with interferon-b1b will be randomized to
additionally receive either high-dose (average daily dose 10.200 IU) or low-dose (average daily dose 200 IU)
cholecalciferol for a total period of 18 months. The primary outcome measure is the number of new lesions
detected on T2-weighted cranial MRI at 3 tesla. Secondary endpoints include additional magnetic resonance
imaging and optical coherence tomography parameters for neuroinflammation and -degeneration, clinical
parameters for disease activity, as well as cognition, fatigue, depression, and quality of life. Safety and tolerability of
high-dose vitamin D supplementation are further outcome parameters.
Discussion: In light of the discrepancy between existing epidemiological and preclinical data on the one hand
and available clinical data on the other the EVIDIMS trial will substantially contribute to the evaluation of the
efficacy of high-dose vitamin D supplementation in MS patients. The study design presented here fulfills the criteria
of a high-quality clinical phase II trial in MS.
Trial Registration: ClinicalTrials.gov Identifier: NCT01440062
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Background
Multiple sclerosis (MS) is the most common chronic
inflammatory disease of the central nervous system
(CNS) in western countries [1]. Based on autoimmune
mediated damage to both glial and neuroaxonal struc-
tures, the disease is not yet curable and therapeutic
options mainly focus on the control of the autoimmune
reaction. The approved therapies include immunomodu-
latory (interferon-b, glatiramer acetate), (selective)
immunosuppressive (fingolimod, azathioprine, mitoxan-
trone) or antibody-mediated (natalizumab) approaches.
Additionally, new drugs are currently under investiga-
tion at different clinical stages. Although efficacy of all
these drugs has been proven in large-scale clinical trials,
some major issues still remain unsolved including partial
efficacy, inconvenience of parenteral application, safety
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and tolerability aspects, insufficient neuroprotective
capacity, and last but not least considerable treatment
costs [2,3]. Against this background the need for an
improvement of therapeutic options in MS remains.
Numerous lines of evidence link both the risk of dis-
ease development and the disease course to the serum
level of 25-hydroxyvitamin D which is the biologically
inactive storage form of vitamin D (extensively reviewed
in [4]): it is long known that the geographic distribution
of MS prevalence depends on latitude which is asso-
ciated with both sunlight intensity and vitamin D serum
levels [5-8]. Particularly, increased sun exposure during
childhood has been consistently shown to decrease the
risk of MS [9-11]. Several epidemiological studies pro-
vide a direct correlation between vitamin D intake and
vitamin D serum levels with both the risk for new dis-
ease development and the course of already established
MS [12-15]. Further evidence for a beneficial role of
vitamin D derives from the experimental autoimmune
encephalomyelitis (EAE), which is the best established
animal model for MS: it has been demonstrated that
treatment with 1,25-dihydroxyvitamin D, the biologically
active form of vitamin D, prevents the development of
murine EAE (preventive approach) [16,17] and, com-
menced at onset of symptoms, reversibly blocks the pro-
gression of disease (therapeutic approach) [17].
Importantly, a recent EAE study provided evidence for a
synergistic effect of a vitamin D analogue and inter-
feron-b [18]. Less clear are the mechanisms of action by
which vitamin D exerts its beneficial effects in autoim-
mune CNS disease. Modulatory effects on cellular and
soluble components of the underlying immune reaction
are probably most important [4,19]. Additionally, pre-
vention of demyelination has also been demonstrated
recently in a model of toxic demyelination [20]. Com-
pared to the large body of existing preclinical data, data
on treatment effects derived from well-designed clinical
trials are scarce, and most clinical trials so far focused
rather on safety and tolerability aspects. Weekly peak
doses of up to 280.000 IU 25-hydroxyvitamin D and
long term treatment with a mean weekly dose of at least
70.000 IU for 36 weeks have been well-tolerated. In par-
ticular, there was no evidence for treatment-related
hypercalcaemia [21,22]. According to a review on the
safety of high-dose vitamin D supplementation, daily
doses of at least 10.000 IU can be considered safe in
individuals with normal renal function [23]. Less clear is
the optimal serum level for immunomodulatory treat-
ment effects and hence the optimal daily dose [24]. A
trend for a reduction of the annualized relapse rate was
observed in clinical trials with daily doses of 5.000 to
10.000 IU, although these studies were not powered to
detect a treatment effect on clinical parameters [22,25].
The effect on MRI parameters is even more obscure.
Accordingly, a recent Cochrane review concluded that
“multi-centered RCTs (randomized controlled trials)
with a focus on clinical as well as immunological and
MRI outcomes (...) are still required” [26].
Against this background, we here present the study
protocol for a randomized controlled clinical phase II
pilot study on the effect of vitamin D supplementation
on MRI in patients with relapsing-remitting MS or clini-
cally isolated syndrome (CIS). We hypothesize, that
high-dose supplementation is superior to low-dose sup-
plementation with respect to imaging parameters includ-
ing MRI and optical coherence tomography (OCT) as
well as clinical parameters.
Methods/Design
Trial design
EVIDIMS is a national, multi-center, stratified, rando-
mized, controlled, and double-blind clinical phase II
trial conducted at approximately ten sites located in or
close to Berlin, Germany. Recruitment will start in 12/
2011. Eighty patients with relapsing-remitting MS or
CIS who are on a stable immunomodulatory treatment
with interferon-b1b will be randomized to either high-
dose (20.400 IU) or low-dose (400 IU) 25-hydroxyvita-
min D supplementation to be taken every other day for
18 months add-on to interferon-b1b. The detailed study
design is provided below according to the revised CON-
SORT statement [27,28]. The study is approved by the
local ethics committee and the German Competent
Authority (Federal Institute for Drugs and Medical
Devices) and is registered at both the European Union
Drug Regulating Authorities (Eudra-CT: 2011-002785-
20) and Clinicaltrials.gov (NCT01440062). The study
will be conducted in accordance to the Declaration of
Helsinki in its currently applicable version, the guide-
lines of the International Conference on Harmonization
of Good Clinical Practice (ICH-GCP), and the applicable
German laws. All participants will be required to give
informed written consent. The trial will be monitored
according to ICH-GCP.
Participants
Inclusion criteria for participation in the EVIDIMS trial
comprise the diagnosis of either definite relapsing-remit-
ting MS according to the revised 2005 McDonald cri-
teria [29] or CIS, an age of 18 to 65 years, a score of
less than 6.5 on the Expanded Disability Status Scale
(EDSS) [30], and being relapse-free for at least 30 days.
All participants are required to be on a stable immuno-
modulatory treatment regimen with interferon-b1b (8
MIU, every other day) for at least three months. In
women of childbearing potential highly effective meth-
ods of birth control defined as a contraception method
with a PEARL-index < 1 and a negative pregnancy test
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at screening is mandatory. The main exclusion criteria
include any other disease course than relapsing-remit-
ting MS or CIS, any disease other than MS that better
explains the symptoms and signs, any immunomodula-
tory or immunosuppressive treatment other than inter-
feron-b1b within the preceding three months, intake of
vitamin D containing products within in the preceding
six months, participation in any other interventional
clinical trial in the last three months, pregnancy or
breast feeding. Additionally, participants may not have
relevant liver, kidney or bone marrow dysfunction or
suffer from sarcoidosis, nephrolithiasis, or hypercalcae-
mia. Concomitant medication with hydrochlorothiazide,
barbiturates, phenytoin, digitalis or other vitamin D con-
taining products is not allowed. To ensure homogeneity
in terms of sunlight intensity and duration as a possible
confounder, patients will be recruited from a single geo-
graphic region (in or close to Berlin, Germany).
Randomization and interventions
Eligibility of patients will be determined at the screening
visit. At baseline visit, patients who qualified for partici-
pation in the study will be stratified according to gender,
disease course, and 25-hydroxyvitamin D serum level at
screening and then randomized 1:1 into two interven-
tion groups. Group A will receive 20.400 IU cholecalci-
ferol orally every other day; group B will receive 400 IU
cholecalciferol orally every other day, which corresponds
to the daily dose recommended by the German Nutri-
tion Society http://www.dge.de. In both arms, vitamin D
treatment will be add-on to a stable immunomodulatory
treatment regimen with interferon-b1b. Regular study
visits are carried out after 1, 3, 6, 9, 12, and 18 months.
Investigations to be performed on the respective study
visits are displayed in table 1. An optional follow-up
visit will be offered 24 months after randomization. If
necessary, additional unscheduled visits can be per-
formed at any time.
Outcome parameters
The primary endpoint is the cumulative number of new
hyperintense lesions on cranial T2-weighted MRI during
the treatment period of 18 months. Additional second-
ary MRI endpoints comprise number and volume of T1-
hypointense and T2-hyperintense lesions, proportion of
patients without any new T1-hypointense and T2-hyper-
intense lesions, number of contrast enhancing lesions,
brain atrophy as determined by normalized brain volu-
metry, and changes in brain metabolism as determined
by magnetic resonance spectroscopy (MRS). All MRI/
MRS investigations will be performed on a 3 tesla MRI
scanner (Siemens, Germany). All MRI parameters will
be assessed by an experienced evaluator who is blinded
to both clinical data and treatment allocation. Secondary
clinical endpoints include the annualized relapse rate
and the proportion of relapse-free patients. A relapse is
defined as de novo development or aggravation or re-
occurrence of a preexisting neurological abnormality
compatible with MS which lasts a minimum of 24
hours, is separated by at least 30 days from a preceding
clinical event and does not occur in the context of fever.
Additional secondary endpoints comprise the disease
progression as determined by EDSS (evaluated by an
independent neurologist), Multiple Sclerosis Functional
Composite (MSFC), cognition as determined by the
Faces Symbol Test (FST) and the Symbol Digit Modal-
ities Test (SDMT), fatigue and depression as well as
quantitative assessment of motor function [31,32]. Addi-
tional parameters include retinal nerve fiber layer thick-
ness and macular volume which are increasingly
recognized as markers for disease progression in MS
[33], visual contrast sensitivity and low contrast visual
acuity, 25-hydroxyvitamin D serum levels, and quality of
life. Assessment of all endpoints will be done by experi-
enced personnel blinded to both the clinical data and
treatment allocation. Peripheral venous blood will be
sampled prior and during the intervention for evaluating
the effect on cellular and soluble components of the
immune system. Safety and tolerability will be assessed
by vital signs, safety lab, ECG, and adverse event report-
ing. The time schedule of all regular evaluations is dis-
played in table 1.
Sample size
Since available data on the effect of vitamin D on the
development of new T2-hyperintense lesions on cranial
MRI are not sufficient for an exact statistical sample
size calculation the study is designed as pilot study with
an a priori determined sample size of 40 patients per
intervention arm, in total 80 patients. Based on this
sample size, a mean reduction of 1.5 new T2-hyperin-
tense lesions in the high-dose treatment compared to
the low-dose regimen will be detected with a power of
0.83.
Blinding
Both, patients and the entire study staff will remain
blinded throughout the complete treatment period of 18
months. Treatment allocations will only be disclosed
after the final database lock. Substantial efforts are made
to maintain blinding: Since high-dose formulation (oil)
does not match the low-dose formulation (tablet),
patients in the high-dose arm will take 400 IU tablets in
addition to 20.000 IU oil, whereas patients in the low-
dose arm will receive an identical volume of placebo-oil
in addition to a 400 IU tablet. The patients are primarily
handled by a treating physician who is in charge of the
evaluation of inclusion or exclusion criteria, adverse
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events, relapses, side effects, etc. All neurological exami-
nations will be done by an independent evaluating phy-
sician. Accordingly, evaluation of all other paraclinical
parameters including MRI and OCT will be done by
independent examiners. Any patient-related crosstalk
between treating and evaluating physicians or examiners
is prohibited unless required because of safety concerns.
An easy unblinding procedure allows for rapid unblind-
ing of a patient in case of a medical necessity. Unblind-
ing inevitably results in the exclusion of the respective
patient.
Statistical methods
Evaluation of endpoints will be carried out by both
intention-to-treat and per-protocol analyses. Statistical
tests and presentation will be appropriate to the cate-
gory and distribution of the respective variables.
Analysis of OCT data will be performed by statistical
models which account for intra-patient inter-eye rela-
tions. The test level for statistical significance of differ-
ences between both treatment arms is defined as p =
0.05 for all tests.
Funding
The EVIDIMS trial is funded in part by a limited grant
of Bayer Vital GmbH, Germany and supported by the
German Research Foundation (DFG Exc 257).
Discussion
In light of the discrepancy between existing epidemiolo-
gical and preclinical data on the one hand and available
clinical data on the other the study design presented
here has the potential to substantially contribute to the
evaluation of the efficacy of vitamin D supplementation
Table 1 Time schedule of regular study visits and outcome parameters
Screening
(Week -2)
V0
(Baseline)
± 7 days
V1(Month
1) ± 7
days
V2
(Month 3)
± 7 days
V3 (Month
6) ± 14
days
V4 (Month
9) ± 14
days
V5 (Month
12) ± 14
days
V6 (Month
18) ± 21
days
Follow up (Month
24) ± 8 weeks
(optional)
Informed consent √
In/exclusion
criteria
√ √
Randomization √
Evaluation of
relapses
√ √ √ √ √ √ √ √ √
Concomitant
medication
√ √ √ √ √ √ √ √ √
Physical
examination
√ √ √ √
Vital signs √ √ √ √ √ √ √ √ √
MSFC √ √ √ √ √
EDSS √ √ √ √ √
ECG √ √
Safety lab √ √ √ √ √ √ √ √
Immunology
blood sampling
√ √ √ √
MRI √ √ √ √
OCT √ √ √ √
Visual contrast
parameters
√ √ √ √
Quantitative
motor function
tests
√ √ √ √
Questionnaires
(fatigue,
depression, QoL)
√ √ √ √ √
Cognitive testing
(SDMT, FST)
√ √ √
Drug account √ √ √ √ √ √
Adverse event
reporting
√ √ √ √ √ √
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in MS and CIS patients. The randomized, controlled,
double-blinded study design and the implementation of
independent evaluation of outcome parameters fulfill
the criteria for a high-quality clinical phase II trial in
MS [34]. Some aspects of the study design however may
deserve a closer discussion: Why was an active treat-
ment regimen instead of a placebo treatment chosen for
the control arm, i.e. low-dose vitamin D? In fact, this
question was heavily debated. Although we do not know
whether this represents rather a causal factor or a con-
sequence, serum levels of 25-hydroxyvitamin D are
often quite low in MS patients [13,35]. Thus, we expect
that low serum levels or even vitamin D deficiency will
be detected in a substantial number of screened study
candidates. From an ethical point of view and bearing in
mind the importance of vitamin D for bone metabolism
it would be difficult not to supplement these patients
with vitamin D. On the other hand, the daily dose pro-
vided in the control arm may not be immunologically
active itself as this would prevent the detection of any
difference between both groups. Thus, the daily dose
recommended by the German Nutrition Society for this
group of age which corresponds to 5 μg or 200 IU and
which most probably has no immunomodulatory poten-
tial represents a compromise between ethical concerns
and efficacy aspects. Another important question relates
to the dose used in the high-dose arm. In fact, we do
not know, at which minimum doses or serum levels
vitamin D starts to have immunomodulatory effects. To
prevent failure of the trial because of an insufficient
treatment dose, we choose the maximum dose for
which sufficient safety data are available, which currently
corresponds to 10.000 IU per day [23]. It might well be
that already smaller doses would be sufficient, but on
the other hand it is rather unlikely, that if this dose
does not demonstrate any treatment effect, even higher
daily doses would do. A further question might be why
an add-on regimen to an established immunomodula-
tory treatment with interferon-b was chosen? In fact,
from a methodological point of view, a monotherapeutic
design would be preferable. However, since disease-
modifying drugs are established and approved for the
treatment of MS it would again be unethical to withhold
these treatment options in favor of an experimental
approach. The restriction to interferon-b as immunomo-
dulatory treatment is explained by the need for maxi-
mum homogeneity in the trial cohort on the one hand
and the reported synergistic effects of interferon-b and
the vitamin D system on the other [18]. Finally, one
might suspect that in view of the rather small sample
size of 80 participants the study might be underpowered
to detect a significant difference between both groups.
However, the study will be able to detect a difference in
mean new T2-hyperintense lesions per year of 1.5 with
a power of more than 0.8. In the pivotal interferon-b1b
trial, verum treatment resulted in a reduction of 2.0
lesions per year as compared to a placebo arm [36].
Thus, if high-dose supplementation with vitamin D is
indeed effective, a reduction of 1.5 lesions per year
would not be unrealistic.
In conclusion, vitamin D has the potential for a safe,
orally available and cheap treatment option in MS and
the EVIDIMS trial may help to close the existing gap
between available promising preclinical and the lacking
clinical data on the immunomodulatory efficacy of vita-
min D in MS.
Trial status
The EVIDIMS trial is currently recruiting patients.
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